Intel stock extends gains after report of possible U.S. government stake
DEER PARK, Ill. - Eton Pharmaceuticals , Inc. (NASDAQ:ETON), a company specializing in rare disease treatments with a market capitalization of $406 million, has announced the launch of Galzin® (zinc acetate) capsules, now available exclusively through Optime Care. Galzin is the only FDA-approved zinc therapy for Wilson disease, a rare genetic disorder that leads to excessive copper accumulation in the body. According to InvestingPro data, the company has demonstrated remarkable market performance, with a 252% return over the past year.
Patients with Wilson disease who have undergone initial treatment with a chelating agent can use Galzin for maintenance therapy. Eton Pharmaceuticals has implemented the Eton Cares patient support program to enhance access to Galzin, promising a $0 co-pay for all eligible patients and comprehensive support services. The company maintains a healthy gross profit margin of 59.3% and operates with moderate debt levels, according to InvestingPro analysis, which offers 8 additional key insights about the company’s financial health.
The Eton Cares program, administered in partnership with Optime Care, aims to simplify prescription fulfillment, insurance benefits investigation, and provide educational support. The program also includes financial assistance and other services designed to help patients access their treatments.
Sean Brynjelsen, CEO of Eton Pharmaceuticals, emphasized the company’s dedication to increasing access and awareness of this crucial medication, acknowledging that affordability issues have previously led patients to seek unapproved or over-the-counter alternatives.
Rhonda Rowland, President of the Wilson Disease Association, expressed optimism about the partnership with Eton to ensure continuous patient access to Galzin. Clinicians can prescribe Galzin electronically by selecting Optime Care as the pharmacy or by faxing a patient referral form.
While Galzin offers a significant therapeutic option for Wilson disease patients, it is important to note potential side effects, including the risk of copper deficiency and gastric ulcers with long-term use. Patients and healthcare providers are advised to monitor for signs and symptoms of these conditions and adjust treatment as necessary.
Eton Pharmaceuticals has a portfolio of seven commercial rare disease products and four additional candidates in late-stage development. The company is committed to further research and development to advance treatment options for rare diseases.
This news is based on a press release statement from Eton Pharmaceuticals, Inc. With annual revenue of $34.7 million and analyst price targets ranging from $21 to $33, the company shows potential for growth. For detailed analysis and comprehensive insights, investors can access the full Pro Research Report available on InvestingPro, which provides in-depth coverage of Eton Pharmaceuticals among 1,400+ US equities.
In other recent news, Eton Pharmaceuticals has been in the spotlight with several noteworthy developments. H.C. Wainwright adjusted its price target for Eton to $33, maintaining a Buy rating, while forecasting a 20% revenue increase to $38.1 million in 2024 and a significant rise to $102.7 million in 2025. This growth is attributed to Eton’s expanding portfolio, including the anticipated FDA decision on ET-400 by February 28 and plans to acquire additional commercial products this year. B.Riley initiated coverage on Eton with a Buy rating and a 12-month price target of $21, citing optimism around Increlex and ET-400 as key revenue drivers, potentially leading to profitability in 2025.
Eton recently reported its first positive GAAP net income quarter, marking 15 consecutive quarters of growth. The company also acquired Galzin, an FDA-approved treatment for Wilson Disease, from TEVA Pharmaceuticals for $7 million. H.C. Wainwright raised Eton’s price target to $17 following this acquisition, highlighting the potential for U.S. commercialization of Galzin in early 2025. Analysts estimate Galzin could generate $0.9 million in revenue in 2025, with growth expected to reach $5.1 million by 2030. These strategic moves underscore Eton’s focus on expanding its commercial product lineup and strengthening its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.